About Ethris
Ethris is a company based in Planegg (Germany) founded in 2009.. Ethris has raised $31.3 million across 5 funding rounds from investors including Gates Foundation, European Union and EU4Health. The company has 59 employees as of December 31, 2023. Ethris operates in a competitive market with competitors including Insitro, BridgeBio, Moderna, GSK and ATAI, among others.
- Headquarter Planegg, Germany
- Employees 59 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ethris Gmbh
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$31.3 M (USD)
in 5 rounds
-
Latest Funding Round
$11.22 M (USD), Grant
May 09, 2025
-
Investors
Gates Foundation
& 3 more
-
Employee Count
59
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Ethris
Ethris has successfully raised a total of $31.3M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $11.22 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $11.2M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Grant - Ethris | Valuation |
investors |
|
| Jun, 2024 | Amount | Series B - Ethris | Valuation |
investors |
|
| Feb, 2022 | Amount | Series B - Ethris | Valuation | Laureus Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ethris
Ethris has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, European Union and EU4Health. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
EU4Health is focused on promoting health policies across Europe.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ethris
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ethris
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ethris Comparisons
Competitors of Ethris
Ethris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Moderna, GSK and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ethris
Frequently Asked Questions about Ethris
When was Ethris founded?
Ethris was founded in 2009 and raised its 1st funding round 10 years after it was founded.
Where is Ethris located?
Ethris is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Is Ethris a funded company?
Ethris is a funded company, having raised a total of $31.3M across 5 funding rounds to date. The company's 1st funding round was a Series B of $26.3M, raised on Oct 01, 2019.
How many employees does Ethris have?
As of Dec 31, 2023, the latest employee count at Ethris is 59.
What does Ethris do?
Ethris was founded in 2009 and is based in Planegg, Germany, where operations focus on biotechnology for mRNA-based treatments. Two proprietary platforms are employed: one for stabilized non-immunogenic mRNA transcript therapy and another for targeted RNA delivery systems. These enable chemical modifications to avoid immune responses and support protein expression. The pipeline targets COVID-19, respiratory conditions, and primary ciliary dyskinesia.
Who are the top competitors of Ethris?
Ethris's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Who are Ethris's investors?
Ethris has 4 investors. Key investors include Gates Foundation, European Union, EU4Health, and Laureus Capital.